Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.66 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 7/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.63 |
| ▸ | POLB | P06746 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | PDE4A | P27815 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.62 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4112577 | 0.89 | MAPT (0.64) | MAPTMEN1KMT2APOLBLMNA | |
| SCHEMBL10576308 | 0.86 | MAPT (0.86) | MAPTMEN1KMT2APOLBLMNA | |
| SCHEMBL4117849 | 0.84 | MAPT (0.73) | MAPTMEN1KMT2APOLBLMNA | |
| SCHEMBL4118152 | 0.84 | LMNA (0.72) | MAPTEPHX2MEN1KMT2ALMNA | |
| SCHEMBL4744609 | 0.83 | NPC1 (0.76) | MAPTEPHX1EPHX2MEN1KMT2A | |
| SCHEMBL4112399 | 0.83 | MEN1 (0.76) | MAPTMEN1KMT2APOLBLMNA | |
| SCHEMBL13969478 | 0.81 | EPHX2 (0.58) | MAPTEPHX1EPHX2MEN1KMT2A | |
| SCHEMBL5174837 | 0.81 | MEN1 (0.73) | MAPTEPHX2MEN1KMT2APOLB | |
| SCHEMBL4111978 | 0.81 | NPC1 (0.75) | MAPTMEN1KMT2APOLBLMNA | |
| SCHEMBL2683478 | 0.80 | EPHX1 (1.00) | MAPTEPHX1EPHX2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | MAPT 1654/4885EPHX1 1972/4885EPHX2 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.